Reidy Christopher R 4
4 · Encompass Health Corp · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
Encompass Health (EHC) Director Christopher Reidy Receives RSU Award
What Happened
- Christopher R. Reidy, a non-employee director of Encompass Health Corporation (EHC), reported acquisitions on April 15–16, 2026. He was credited 19 restricted stock units (RSUs) on April 15 (reported at $0.00) and acquired 334 shares on April 16 at a weighted average price of $106.48, for a reported cash value of $35,564. These transactions are awards/purchases, i.e., acquisitions rather than sales.
Key Details
- Transaction dates and prices:
- 2026-04-15: Award (RSUs) — 19 shares, $0.00 reported (see F1).
- 2026-04-16: Acquisition (market purchases via plan) — 334 shares, weighted avg $106.48, total $35,564 (see F2 & F3).
- Shares owned after transaction: Not provided in the summary data supplied.
- Notable footnotes:
- F1: 19 RSUs credited as the dividend reinvestment award tied to the $0.19 per-share dividend paid April 15, 2026 (closing price $105.24 used to calculate RSUs).
- F2: 334 shares were purchased by the Directors Deferred Stock Investment Plan using deferred director fees and reinvested dividends.
- F3: $106.48 is a weighted average; purchases occurred at prices from $106.21 to $106.48. The reporting person can supply the per-trade breakdown on request.
- Filing timeliness: Report filed April 16, 2026 for transactions through April 15, 2026 — appears timely.
Context
- These were acquisitions: a dividend-credit RSU award and purchases made under a director deferral plan (i.e., the company-administered plan used to buy shares with deferred fees and reinvested dividends). Awards and purchases by insiders are factual disclosures and do not, by themselves, indicate motivation.
Insider Transaction Report
Form 4
Reidy Christopher R
Director
Transactions
- Award
Encompass Health Common Stock
[F1]2026-04-15+19→ 15,469 total - Award
Encompass Health Common Stock
[F2][F3]2026-04-16$106.48/sh+334$35,564→ 15,803 total
Footnotes (3)
- [F1]Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
- [F2]The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.
- [F3]This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.21 to $106.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
Signature
/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy|2026-04-16